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A systematic approach based on bacteriophage  ( Red) and flippase-flippase recognition targets (FLP-
FRT) recombinations was proposed for genomic engineering of Escherichia coli. For demonstration 
purposes, DNA operons containing heterologous genes (i.e. pac encoding E. coli penicillin acylase and 
palB2 encoding Pseudozyma antarctica lipase B mutant) engineered with regulatory elements, such as 
strong/inducible promoters (i.e. Ptrc and ParaB), operators, and ribosomal binding sites, were integrated into 
the E. coli genome at designated locations (i.e. lacZYA, dbpA, and lacI-mhpR loci) either as a gene 
replacement or gene insertion using various antibiotic selection markers (i.e. kanamycin and 
chloramphenicol) under various genetic backgrounds (i.e. HB101 and DH5α). The expression of the 
inserted foreign genes was subject to regulation using appropriate inducers [Isopropyl β-D-1-
thiogalactopyranoside (IPTG) and arabinose] at tuneable concentrations. The developed approach has 
paved an effective way to “tailor” plasmid-free E. coli strains with desired genotypes suitable for various 
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Escherichia coli (E. coli) has been long recognized as a versatile host system for manufacturing of 
both ribosomal and non-ribosomal products primarily due to the availability of various powerful 
biotechnologies associated with this microorganism. The extensive development of genetic tools and 
protocols enables the manipulation and engineering of E. coli strains suitable for industrial 
applications. Among them, recombinant DNA technology, developed in the 1970s, has opened an 
avenue for introducing foreign genes via shuttle vectors, such as plasmids, into E. coli host cells for 
gene expression. The plasmid-based over-expression of genes in E. coli has proven to be useful for 
recombinant protein production (1). In addition to protein overproduction, recombinant DNA 
technology has been commonly used to graft foreign genes into E. coli host cells for metabolic 
engineering purposes, such as the production of non-natural metabolites (2-4). However, there are 
intrinsic limitations associated with these plasmid-based applications. For example, the energy 
required to maintain and propagate a plasmid comes from cellular resources of the host. Furthermore, 
high-copy number plasmids could lead to unnatural and deleterious dosing of the grafted genes, 
causing significant stress to host cells (5). Such energy related stress to the cell is generally referred 
to as metabolic burden. On the other hand, recombinant cells could be genetically unstable provided 
the grafted foreign genes are carried by a low-copy number plasmid. To address these technical 
issues, integrating foreign genes into the E. coli genome appears to be a plausible solution. 
In addition to traditional protocols for manipulating the E. coli genome, such as random 
mutagenesis, conjugation, transduction, etc., consistent yet low-level interest has been shown in 
genome-based expression platforms (6, 7). However, early systems suffered several technical 
drawbacks and limitations, including labor-intensive, time-consuming, dependent upon specific 
mutant strains, only applicable to suicide or non-replicative plasmids, and difficult to target to a 
specific chromosomal locus. Examples include plasmid integration in replication-deficient polA 
mutants (8), random Tn1545-mediated plasmid insertion (9), chromosomal integration of linear 
substrates in recBCD (10), recBC sbcB (11), or recD (12) mutants, FLP recombination of suicide 
plasmids targeted to a single chromosomal FRT site (i.e. the FLIRT system) (13), and suicide 
plasmid integration and cointegrate resolution via I-SceI meganuclease-stimulated double strand 
break (14).  
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Recently, the advent of genomic editing strategies based upon the recombination systems 
from the Rac prophage (i.e. RecET) (15) or the bacteriophage λ Red operon (i.e. Exo, Bet, and Gam) 
(16, 17) allow rapid, universal, and specific genomic manipulation. Basically, an exogenous DNA 
fragment carrying two homologous arms on both ends and containing an antibiotic marker gene 
flanked by two FRT sites is prepared by PCR-amplification of a defined region in a template vector. 
The PCR product is then transformed into E. coli cells and undergoes site-specific homologous 
recombination mediated by either RecET or λ Red proteins in order to replace the targeted gene. The 
antibiotic marker is subsequently removed from the genome by FLP-FRT recombination to generate 
an antibiotic marker-less mutant derivative. A comprehensive E. coli mutant library, known as the 
Keio collection (18); www.shigen.nig.ac.jp/ecoli/strain/top/top.jsp), was made by using the λ Red 
recombination protocol to inactivate various non-essential genes. 
Almost all genomic engineering protocols have been developed for the purpose of 
inactivating chromosomal genes. The capacity for integrating heterologous genes into E. coli genome 
to extensively “tailor” E. coli strains for various biotechnological applications is worth exploring. 
1.2 Research Objectives 
The overall objectives of this thesis are as follows: 
i) Demonstrate a systematic approach based on λ Red and FLP-FRT recombinations to 
integrate heterologous genes into the E. coli genome through either gene replacement or 
gene insertion. 
ii) Demonstrate that the expression of the integrated genes can be tunable by controlling the 
inducer concentration in the medium. 
1.3 Outline of thesis 
This thesis consists of six chapters. The scope of each chapter is as follows: 
 Chapter 1 contains an introduction to the thesis, including an overview of plasmid-based 
expression of genes and the limitations. The hypothesis, objectives and the scope the thesis are also 
given in this chapter. 
Chapter 2 reviews commonly used methods for the genetic engineering of E. coli for gene 
deletions, insertions and replacements. This chapter also includes a brief introduction of gene 
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expression systems and proteins used to demonstrate advanced recombineering method developed in 
this study.  
Chapter 3 describes the methods used to construct various plasmids and strains used in this 
study, and the analytical methods used to confirm and characterize the mutant strains derived in this 
study.  
Chapter 4 presents the results of the gene replacement and gene insertion experiments, as 
well as the results from studies on the tunable expression of these genes. 
 Chapter 5 summarizes the proposed gene knock-in method and discusses technical aspects 
associated with it.  




Chapter 2  
Literature Review 
2.1 Escherichia coli: The most widely used host for biotechnological and 
pharmaceutical applications 
Numerous important factors must be considered before choosing a host for the heterologous 
expression of a protein, including cell growth characteristics, gene expression levels, post-
translational modifications, and government regulations regarding therapeutic proteins (19, 20). 
Many well-established expression systems exist, including those derived from yeast (21, 22), bacteria 
(20, 23, 24), fungi (25, 26), insect cells (27) and mammalian cells (28, 29). 
With a well-characterized genome, a number of cloning and expression vectors and mutant 
strains, and the ability to grow rapidly to a high density on minimal media, E. coli became a model 
organism in biology since its discovery in 1919 (20). In fact, the creation of the first recombinant 
DNA by Stanley Cohen and Herbert Boyer in 1973, which is considered as the birth of biotechnology 
by many, was first established in this bacterium (30). The production of human insulin as the first 
functional recombinant protein from E. coli in 1980 was another major milestone (31, 32). Since 
then, many therapeutic proteins have been produced by recombinant strains of E. coli. Between 2003 
and 2006, 9 out of 31 biopharmaceuticals approved by the United States Environmental Protection 
Agency have been produced in E. coli (34). 60% of recombinant genes reported in journals 
catalogued in PubMed between 1995 and 2009 have been expressed in E. coli (35). Despite a few 
disadvantages, such as the lack of post-translational processing abilities in this bacterium required for 
many eukaryotic proteins, lack of protein secretion and very low disulfide bond formation within 
transcribed proteins (20), E. coli retains its popularity as one of the most versatile hosts for 
recombinant protein production (1). 
The genetic engineering method studied here has been developed in E. coli because of its use 
as a model organism, and its application in many areas of biology.  
2.2 E. coli expression vectors 
Bacterial plasmids are double-stranded closed circular DNA molecules, either naturally occurring in 
bacteria or man-made. An expression vector is an artificial bacterial plasmid used for expressing a 
gene encoding a protein of interest within a bacterial cell. Man-made vectors consist of all features 
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required for the maintenance of the plasmid within the bacterial cell, and the expression of the gene 
of interest. These features are summarized in Table 2.1. 
Table 2.1: Components of Expression Vectors 
Expression vector 
component 
Function Example of component 







An ori is a sequence of DNA where replication is 
initiated. This sequence also determines the vector copy 
number in a cell. Cells with plasmids with low copy 
number ori, such as pMB1(33), typically have 25-50 
plasmid copies per cell. Higher copy numbers, between 
150-200 plasmid copies per cell, can be achieved using a 
high copy number ori such as the pUC ori (34).  
ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff
ffffffff                             
pUC ori, pMB1 ori, pACYC 











Selectable markers are antibiotic resistance genes 
required for the maintenance of the plasmid in the cell. 
These genes also allow for the selection of cells 
containing the plasmid. Under selective conditions, only 


















The ribosome binds to the RBS to initiate protein 
translation. This sequence is six base pairs long and is 
usually 8 nucleotides upstream of the start codon (AUG) 
in bacteria. In prokaryotes, the RBS is referred to as the 
Shine-Dalgarno sequence (20). 
 
Consensus sequence of 
AGGAGG.  
Promoter and regulatory 















Promoters are short regulatory sequences found 
upstream of the RBS which bind the transcription 
complex to initiate transcription of a gene. Prokaryotic 
promoters consist of two short nucleotide sequences at 
10 and 35 nucleotides upstream from the transcription 
start site, and these sequences are called -10 and -35 
elements. The conserved sequences of the -10 and -35 
elements are TATAAT and TTGACAT respectively, 
although only about three out of six base pairs are found 
in a given promoter (20).  
 
Promoters can be grouped into constitutive and inducible 
promoters. Constitutive promoters allow for continues 
transcription of a gene, whereas inducible promoters are 
activation by chemicals (such as Isopropyl β-D-1-
thiogalactopyranoside or lactose) (20, 24, 35, 36), 
temperature change (37), or other physical factors. Ideal 
promoters for recombinant protein production should be 
Trc promoter (Ptrc), araB 
promoter (ParaB), T7 







inducible, strong enough for high transcription rate, and 
have very little basal activity when uninduced. 
 
Other regulatory elements might include, operator 
regions, and genes encoding for repressors and 
transcription terminators. Repressors inhibit 
transcription in the absence of an inducer by binding to a 
sequence between the promoter and genes of the operon. 
This sequence is called the operator region (24, 38, 39). 
For example, the lacI repressor inhibits transcription 
from lac-derived promoters by binding to the operator 
sequence within this operon. Inducers cause an allosteric 
change in the repressor molecule such that the repressor 
is unable to bind to the operator sequences. Thus, 
inducers allow for transcription from these promoters. In 
the case for lac-derived promoters, the lacI repressor 
molecule is allosterically modified by IPTG or 
allolactose, which allows for transcription from these 
promoters (40). 
 
Transcription terminators are sequences at the end of a 
gene that end transcription. Two types of transcription 
terminators are available for E. coli vectors. With 
intrinsic transcription terminators, the transcribed 
mRNA forms a hairpin structure, disrupting the mRNA-
DNA-RNA polymerase complex. The second type is the 
Rho-dependent terminators, where a RNA helicase 
protein called Rho factor disrupts the mRNA-DNA-
RNA polymerase, thus ending transcription (20). 
  
Multiple Cloning Site 






Also called a polylinker, the MCS is a short sequence 
within the expression vector consisting of up to 20 
single-cutting restriction sites. These restriction sites are 
used to sub clone the gene encoding the protein of 
interest into the vector. The MCS is usually downstream 
of the promoter region such that the promoter can drive 
the transcription of the sub cloned gene (20). 
The MCS is composed of 
various restriction sites. 
Some of the commonly 
used restriction enzymes 
to sub clone a gene into 
the pUC19 MCS, for 
instance, are EcoRI, 
HindIII, BamHI, and PstI. 
 
 
2.2.1 Recombinant protein production from pET expression vectors 
Several expression vectors exist for recombinant protein production in E. coli. Of these, pET 
expression vectors based on the T7 promoter (PT7) are few of the most commonly used expression 
vectors (41, 42). This expression system is used within host strains of E. coli with a chromosomally 
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integrated T7 RNA polymerase gene regulated by the lacUV5 promoter. Upon induction by IPTG, 
the T7 RNA polymerase is expressed from the genome. The T7 RNA polymerase binds specifically 
to the PT7 region, and promotes high level transcription of the recombinant proteins. Up to 50% of the 
total cellular protein content is reached after only a few hours of induction by IPTG (36) (20, 42).  
It is necessary for the E. coli host strain to contain a chromosomally integrated gene encoding 
the T7 RNA polymerase gene (20). The DE3 strains of E. coli, such as the E. coli BL21 (DE3) 
strains, are commonly used with this system since they contain the λ prophage carrying the T7 RNA 
polymerase and lacI
q 
genes. In this study, bacteriophage  based genomic engineering was attempted 
in E. coli BL21 (DE3). However, no transformants were derived via electroporation or P1 phage 




Figure 2.1 pET vectors. The gene encoding protein of interest is sub cloned into the multiple 
cloning site (MCS) downstream of the T7 promoter (T7). The antibiotic resistance genes, either 
ampicillin resistance gene (Ap) or Kanamycin resistence gene (Kn), are used for selection of E. 
coli transformants carrying these plasmids. The pBR322 origin of replication (ori) is used in 





2.2.2  Recombinant protein production using regulatory elements from E. coli lac operon 
This operon consists of three genes, lacZ, lacY and lacA (lacZYA) that encode for β-galactosidase, 
lactose permease and transacetylase respectively enzymes necessary for the utilization of lactose. The 
Plac and operator genes are directly upstream of the lacZYA genes. The lacI gene, encoding for the 
transcriptional repressor molecule, is about 120 nucleotides upstream of the lacZYA genes (Figure 
2.2) (20, 24, 40, 43).  
 
Figure 2.2 E. coli lac operon. The lacI repressor, promoter (P) and operator (O) genes are 
found upstream of the lacZYA genes. Binding of the CAP molecule to the CAP site increases in 
the presence of glucose, driving the transcription of the lacZYA genes by inducing the lac 
promoter.  
In the absence of lactose, the lacI repressor binds to the operator sequence, inhibiting the 
RNA polymerase from binding to the promoter. The lactose metabolite allolactose, IPTG, and other 
β-galactosides allosterically change the conformation of the repressor molecule such that it is unable 
to bind to the operator. In the absence of this repressor inhibition, the RNA polymerase binds to the 
operator sequence and initiates transcription. Thus, lactose and IPTG are able to induce expression of 
the lacZYA genes (20, 24, 40, 43). 
Expression systems based on the lac operon take advantage of the lac regulatory apparatus; 
the promoter (including the operator sequence) and the lacI repressor genes. A gene encoding a 
protein of interest is sub-cloned in an expression vector carrying these regulatory genes, with the Plac 
upstream of the protein encoding gene, and transformed into an E. coli host strain. Thus, high level 
expression of the recombinant protein is induced by adding a β-galactoside in the media. The most 
common inducer used for this system is IPTG since it cannot be cleaved by β-galactosidase, is very 
stable in cells and induces the Plac at very low concentrations (24). 






The wild-type lac operon is also repressed by glucose by the use of the catabolite gene 
activator (CAP), a protein encoded by the crp gene. In the absence of glucose, cyclic AMP (cAMP) is 
produced. CAP binds to cAMP molecules and the CAP-binding site (Figure 2.2) to enhance 
expression of the lac operon. To facilitate stronger expression of recombinant proteins from 
expression vectors, the lacUV5 mutant promoter (PlacUV5) is used.  Binding of CAP to the CAP site 
has relatively little effect on transcription with the lacUV5 promoter. Thus increased protein 
expression is achieved in rich fermentation media that contain glucose and other carbon sources that 
would otherwise inhibit transcription via CAP (24). 
Significant level of basal expression is still present in the absence of an inducer from both 
Plac and PlacUV5. To overcome this “leaky” expression, the lacI repressor gene can be over-expressed. 
Alternatively, the lacI
q
 repressor can be used instead of the wild-type repressor to similarly fine-tune 
regulation. The lacI
q
 repressor binds to the operator more tightly than the wild-type repressor, thus 
also decreasing the basal level of expression. Both methods are equally effective, decreasing basal 
level expression up to ten folds (20, 24). 
The expression systems derived from the lac operon can be used in virtually any E. coli host 
strain. These systems has been studied extensively and optimized for heterologous protein 
expression. However, the expression level is still lower relative to other prokaryotic promoters. It has 
been proposed that this lower expression level is due to the differences between the sequences of the 
-35 (TTTACA) and -10 (TATGTT) elements of Plac, from the E. coli consensus sequences for these 
elements (TTGACA and TATATT, respectively). More specifically, the G/T difference in the -35 
region has detrimental effects on protein expression (20). This problem has been alleviated by the 
engineering of trp/lac-hybrid promoters, which are reviewed in section 2.2.4. 
2.2.3  Recombinant protein production using regulatory elements from E. coli trp operon 
Similar to lac-based expression vectors, expression vectors based on the inducible genetic elements 
from the trp operon have also been design. The trp operon encodes for five enzymes that catalyze the 
biosynthesis of tryptophan (43). This operon was the first repressible operon discovered. Whereas 
Plac is activated by chemicals (allolactose, IPTG), the trp promoter (Ptrp) is repressed by tryptophan. 
The Ptrp system includes the repressor encoded by the trpR gene. Repression occurs when tryptophan 
binds to the repressor molecule, which in turn binds to the operator. Thus, addition of tryptophan into 
the fermentation media effectively blocks transcription (38, 44). This promoter can be used for over-
expression of heterologous protein in any E. coli host background. 
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2.2.4 Recombinant protein production from trp/lac-hybrid promoters 
As mentioned in section 2.2.2, expression vectors based on the lac-operon yield low levels of 
recombinant protein expression compared to other expression systems primarily due to the difference 
between the Plac -35 element sequence and the E. coli conserved -35 sequence. To overcome this 
disadvantage, the Ptrp/PlacUV5-hybrid promoters were designed. 
The tac (Ptac) and trc (Ptrc) promoters consist of the -35 element of Ptrp, and -10 element and 
operator sequence of PlacUV5. Thus, these hybrid promoters maintain the consensus sequence for -35 
and -10 elements of other E. coli promoters. Expression vectors carrying these promoters also contain 
of the lacI
q
 gene since these promoters are repressed by the lacI
q
 repressor molecule similar to Plac 
and PlacUV5; therefore, these hybrid promoters can be easily induced by IPTG as well (36, 45, 46).  
The only difference between the two hybrid promoters is the consensus sequence between -35 and 
-10 elements of each promoter (39, 46). This sequence is 16 nucleotides long in Ptac , which is one 
nucleotide less than that of Ptrc. However, expression levels of genes by Ptac and Ptrc are similar;  -
approximately 11 folds higher than PlacUV5 expression level, and approximately 3 folds higher than 
Ptrp expression level (36). 








Figure 2.3 pTrc99a plasmid. The vector contains a multiple cloning site (MCS) downstream of 
the trc promoter (Ptrc), a pBR322 origin of replication (ori), lacI
q 
repressor gene, an ampicillin 
resistance gene (ApR), and multiple rho-dependent transcription terminators (rrnB). The trc 
promoter consists of the -35 element of trp promoter and -10 element of lac promoter.  
2.2.5 Recombinant protein production using regulatory elements from Salmonella typhimurium 
araBAD operon 
Promoters that respond to chemical inducers other than β-galactosides are necessary for the selective 
co-expression of multiple heterologous genes from a single host strain. The pAR3 plasmid is a gene 
expression vector bearing arabinose-inducible genetic elements from the arabinose operon (araBAD 
operon) of Salmonella typhimurium (S. typhimurium) (35, 43). This vector allows for differential co-
synthesis of enzymes in a single E. coli host when used in combination with an IPTG-inducible 
promoter-based expression vector.  
 The pAR3 vector was engineered by sub-cloning the araC repressor gene, the araB promoter 
(ParaB) and operator sequences, and the araB ATG start codon in the MCS of the pACYC184 vector 
(Figure 2.4). In S. typhimurium cells, these genetic elements induce the expression of three genes 
essential for arabinose catabolism in the presence of arabinose; araB, araA and araD encoding for 
ribulokinase, arabinose isomerase and ribulose 5-phosphate 4-epimerase, respectively (43). Genetic 
analysis and DNA protection of araC repressor protein and gene from E. coli and S. typhimurium 
suggest that the araC repressor protein acts as both the repressor and activator of transcription of the 
araBAD genes. The repressor molecule binds to two positions on the araBAD operator in the 
presence of arabinose, facilitating the initiation of transcription by RNA polymerase. The repressor 
molecule binds to two different positions on the araB operator in the absence of arabinose, catalyzing 
the formation of a DNA loop structure to efficiently repressing the transcription of the araBAD genes 




Figure 2.4 pAR3 expression vector. The araC repressor gene and araB promoter and operator 
sequences (araBpo) from the S. typhimurium genome were sub-cloned into the BstBI and NcoI 
sites of pACYC184 plasmid to yield the expression plasmid pAR3. This vector also has a 
pACYC184 origin of replication (ori) and chloramphenicol resistance gene (Cm
R
). 
2.3 Commonly used genetic engineering strategies 
Genetic engineering refers to the manipulation of an organism’s genome for the synthesis of 
economically valuable bio-products, change of hereditary traits, or both. Several innovative strategies 
have been created for genetic engineering in E. coli (6, 9, 10, 14, 16, 49-54). This section reviews 
three recently devised and commonly used strategies, and the advantages and disadvantages 
associated with them. 
2.3.1 Transposon-mediated insertions: Tn5 Transposon technology 
Transposons are a type of mobile genetic elements. They are relatively short pieces of DNA that 
move or replicate by inserting themselves into other pieces of DNA in a bacterial genome. The Tn5 
transposon consists of an antibiotic resistance gene flanked by sequences of terminal repeats and 
genes encoding transposition functions. Insertional mutagenesis can be achieved by electroporations 




Figure 2.5 A schematic representation of the Tn5 transposon. The genes encoding the antibiotic 
resistence gene and transposition functions are shown. IS50L and IS50R are insertion 
sequences. 
 
Transposons inactivate genes by insertions, thus knocking out the gene. There are several 
advantages of transposon mutagenesis over other mutagenesis techniques. Bacterial transposons 
cannot insert into human DNA, making them safer than chemical and ionizing radiation. Although 
transposition frequency is low, insertional mutagenesis can be selected for by the antibiotic due to the 
antibiotic resistence gene within the transposon. Moreover, because of the low transposition 
frequency, transposons usually only lead to one mutation per cell.  
Despite the advantages, there are many aspects the limit the use of this technology. 
Transposons randomly insert themselves into genes. Thus, directed-mutagenesis is not possible using 
the Tn5 transposon technology. Also, the transposon can move into other places of the genome after 
integration into the first site. Finally, this technology is only limited to gene knock outs. Often, 
insertion of a transposon element in a gene downregulates the expression of downstream genes as 
well.  
2.3.2 FLP recombinase-mediated gene insertions: The FLIRT system 
The FLP-mediated DNA Integration and Rearrangements at prearranged genomic Targets (FLIRT) 
system is based on the flippase (FLP) system from the 2µ circle, a 6.3 kb natural plasmid found in the 
nuclease  of most Saccharomyces cerevisiae (S. cerevisiae) strains (13). In S. cerevisiae, the FLP 
protein recognizes two Flippase Recognition Targets (FRT sites) on the genome, and removes any 
DNA sequence between these sites by catalyzing homologous recombination using these sites. This 
recombination removes any genes within that DNA sequence, and leaves behind one FRT site at the 
site of excision (13). 











The FLIRT system allows for gene integrations in the E. coli genome by employing the yeast 
FLP/FRT recombination mechanism in E. coli. First, FRT sites are introduced at random positions in 
the E. coli genome by a Tn5 transposon technology. A “suicide” vector containing an FRT site, 
selectable marker, origin of replication and an exogenous gene of interest is introduced into an E .coli 
strain by electroporation. Regulated expression of the FLP gene from another compatible expression 
vector provides the FLP protein that mediates the homologous recombination between the FLP sites 
on the E. coli chromosome and the cloning vector, efficiently integrating the suicide vector (including 
the exogenous genes) into the genome (13).  
Although the FLIRT method yields mutant E. coli strains at relatively high efficiencies, a few 
drawbacks limit the use of this system. First, integration of antibiotic markers into the chromosome 
along with the exogenous gene is required to select for desired recombinants. Since there are very 
few commonly used antibiotic resistance markers used for E. coli, this limits the number of genes that 
can be integrated in the genome. Second, this method is cannot be used for integrating genes at pre-
selected sites in the genome since the FRT sites are introduced at random sites using the Tn5 
transposon system. Finally, this long genetic engineering protocol can only be used to insert DNA 
sequences into the genome. Gene deletion and replacements are not possible with the FLIRT method. 
2.3.3 -Red mediated gene deletions: Recombineering 
Recombineering (recombination-mediated genomic engineering) (55) is a popular method used for 
gene deletion in E. coli based on homologous recombination using recombination proteins from the  
phage. The -Red genes encoding the three recombination proteins, exo, bet, and gam, are expressed 
from an arabinose-inducible promoter from an expression plasmid (the pKD6 vector, see Table 3.1).  
A double-stranded linear DNA fragment, PCR-amplified from template plasmids pKD3 or pKD4 
(see Table 3.1), containing sufficient 5’ and 3’ end homology to the target chromosomal DNA 
sequence, and an FRT-flanked antibiotic resistance gene, is first transformed into the desired E. coli 
strain bearing the pKD46 plasmid. Induction of the -Red genes by arabinose from pKD6 produces 
the three recombination proteins in the strain. The exo protein is a 5’-3’ exonuclease that creates 
single-stranded overhangs on the linear DNA (56). The gam protein prevents degradation of the 
linear DNA by inhibiting the E. coli exonuclease V protein (encoded by the recBCD) (57, 58) . The 
bet protein protects these overhangs and directly assists in homologous recombination, efficiently 
replacing the target gene with the linear DNA sequence (59). The mutant strain can be cured of the 
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pKD46 plasmid by increasing the culturing temperature to above 32ºC since this plasmid contains a 
temperature sensitive replication of origin (sc101 ori) (16). This final step yields plasmid-free strains 
of E. coli with the desired gene deletion. 
 Apart from genomic engineering, recombineering has also been used to modify E. coli 
vectors and Bacterial Artificial Chromosomes (BACs) in vivo (60, 61). Arabinose-inducible 
expression of the FLP gene from another temperature sensitive plasmid can be used for the 
FRT/FLP-mediated removal of the antibiotic resistance gene from the integrated sequence to yield 
marker-less mutant strains (16). Removal of the marker gene allows for multiple consecutive gene 
deletions in E. coli.  
 Recombineering is a versatile tool for deleting DNA sequences from the E. coli genome. 
Other than in the Gene Gorging method (Section 2.3.4), the recombineering method has not been 
further developed for gene insertions or replacements in E. coli, which limits the use of this method 
for genomic engineering. 
 A collection E. coli K12 strains consisting of single-gene deletions of all non-essential genes 
has been constructed using this method (18). This collection, termed “Keio collection”, is available at 
The Coli Genetic Stock Center at Yale University, New Haven, Connecticut. 
2.3.4 I-SceI meganuclease-mediated gene replacement: The Gene Gorging method 
The gene gorging method is based on the -Red recombination proteins (see section 2.3.3) and I-Sce 
endonuclease. In this method, two plasmids are introduced into the host strain: 1) a donor plasmid 
contains the exogenous gene with 5’ and 3’ sequences homologous to the target gene and an I-SceI 
endonuclease site, and 2) a recombineering plasmid, designated pACBSR, carrying the -Red and I-
SceI endonuclease genes under the control of ParaB. Upon arabinose induction, the I-SceI cleaves the 
donor plasmid, providing the double-stranded linear DNA substrate for the -Red proteins. 
Homologous recombination catalyzed by the -Red proteins replaces the target DNA sequence on the 
chromosome with the exogenous DNA in the linearized donor plasmid. The frequency of integration 
is relatively high (1-15%) because of presence of multiple copies of linear DNA present in the cells 
(62). Due to this high integration frequency, simple screening methods such as colony PCR can be 
used for isolation of desired recombinants, eliminating the need for integration of selection markers. 
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 Although this method yields genetically engineered E. coli strains without antibiotic 
resistance genes, the integration frequency is not very consistent. Moreover, this method has had 




Chapter 3  
Materials and Methods 
3.1 Bacteria and plasmids 
The bacterial strains and plasmids used in this study are listed in Table 3.1. Pfu polymerase, 
restriction enzymes and Quick Ligation kits were purchased from New England Biolabs (Beverly, 
MA). Plasmid DNA purification, gel extraction and PCR purification were performed using spin 
column kits purchased from Bio Basic Inc. (Markham, ON). The Micropulser from Bio-Rad 
(Hercules, CA) was used for plasmid and linear DNA transformation. L-arabinose was purchased 
from Sigma-Aldrich (St. Louis, MO). All bacterial cultures were grown in lysogeny broth (LB) (5 g/l 
NaCl, 5 g/l Bacto yeast extract and 10 g/l Bacto tryptone). Media and agar plates were supplemented 
with 100 ug/ml ampicillin (Ap), 10 ug/ml chloramphenicol (Cm), or 25 ug/ml kanamycin (Kn) 
resistant transformants when necessary. 
Plasmids pTrc100catPAC and pAr4KnPalb were constructed for use as template plasmids for 
Polymerase Chain Reaction (PCR) (Figure 3.1). The FRT-flanked chloramphenicol resistant (Cm
R
) 
gene was PCR-amplified from pKD3 (16) with the HindIII-Cmcass.F and PstI-Cmcass.R primers 
(Table 3.1). The amplified DNA fragment was digested with HindIII and PstI and ligated to the 
multiple cloning site (MCS) in the similarly digested pTrc99A (45) to form pTrc100cat. The pac 
gene was PCR-amplified from pTrcKnPAC2902 (63) with the pac-Fw and pac-Rv primers, and the 
fragment was digested with EcoRI and PstI and ligated in the MCS of the similarly digested 
pTrc100cat to form pTrc100catPAC. Similarly, the FRT-flanked kanamycin resistance (Kn
R
) gene 
was PCR-amplified from pKD4 (16). The PCR fragment was digested with HindIII and PstI and 
ligated into the MCS of similarly digested pAR3 (35) to form pAr4Kn. The palB2 gene was PCR-
amplified from the pETGM2 (64), digested with NdeI and KpnI and ligated into the MCS of similarly 





Table 3.1: Strains, Plasmids and Oligonucleotides 
Strain Relevant Genotype Source & Reference 








) gal λ(DE3[lacI ind1 
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DH5α 
F'(80 dlac Δ(lacZ)M15) Δ(lacZYA-argF)U169 deoR 




) phoA supE44 lambda-thi-1 
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-FRT  This study 
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HB101PACPalB2 HB101 Δ(lacZYA) Ptrc::pac ParaB::palB2 This study 
HB101PACPalB2KnR HB101 Δ(lacZYA) Ptrc::pac ParaB::palB2 FRT-Kn
R
-FRT This study 
S. marscescens   
ATCC27117 Penicillin-G resistant, 6-APA-sensitive ATCC 
Plasmid   
pAR3 Expression vector, pACYC184 ori, ParaB, Cm
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 (35) 
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pETGM-2 Expression vector, pBR322 ori, PT7::palB2, Ap
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lacI.mhpR seqF 5’-TATCAACTGGCACGGGAACCGTTA-3’ 












Figure 3.1 Template plasmids. A) Most expression or cloning vectors can be used to derive the 
template vector. The open reading frame(s) (ORF) of the gene(s) of interest and the antibiotic 
marker gene (2
nd
 antibiotic marker) flanked with the FRT sites can be cloned into the multiple 
cloning sites (MCS). Specialized gene regulatory elements, such as an activator or repressor 
(Rep), promoter (P), operator (O), ribosome binding site (RBS) and terminator (T), can be 
adopted to regulate the expression of the heterologous gene(s). Alternatively, native regulatory 
elements of the heterologous gene(s) can be used. B) Plasmid pTrc100catPAC was derived from 
pTrc99a plasmid. The template plasmid consists of the trc promoter (P(trc)) regulated PAC 
gene (PAC), the repressor gene (lacIq), ampicillin resistance gene (ApR), and FRT sites flanked 
chloramphenicol resistance gene (CmR). C) Plasmid pAR4KnPalb was derived from pAR3 
plasmid. pAR4KnPalb consists of the araB promoter (P(araB)) regulated lipase gene (lipase), 





All strains were constructed using the λ Red and FLP-FRT recombineering protocols 
reported previously (16). The large linear DNA inserts used in the recombineering experiments were 
amplified from the template plasmids of pTrc100catPAC and pAr4KnPalb using touchdown PCR 
(68), followed by DpnI digestion for 2 h to remove template plasmids from the reaction mixure. H2s-
P2as.lacZYA.KO and H1as-P1s.lacZYA.KO primers were used for PCR-amplification of the pac 
operon from pTrc100catPAC. Similarly, H2s-P2s.dbpA.KO and H2as-P2as.dbpA.KO primers were 
used to PCR-amplify the palB2 operon from pAr4KnPalb. HB101PAC
 
is an E. coli mutant derived 
from HB101 by replacing the chromosomal lacZYA genes with the pac gene. The HB101PACPalB2 
and DH5αPalB2 strains were similarly engineered, replacing the chromosomal dbpA gene with the P. 
antarctica palB2 in HB101PAC and DH5α, respectively. The FLP-FRT recombination was used to 
remove the antibiotic marker genes on the genome. To construct HB101PACins, the pac gene was 







Figure 3.2 Replacement of lacZYA with pac: The pac operon was PCR-amplified based on the 
template plasmid, pTrc100catPAC using the primer pair (i.e. H1as-P1s.lacZYA.KO and H2s-
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Figure 3.3 Replacement of dbpA with palB2: The palB2 operon was PCR-amplified based on 
the template plasmid, pAr4KnPalB2 using the primer pair (i.e. H3s-P3s.dbpA.KO and H4as-























































Figure 3.4 Insertion of pac into the junction between lacI and mhpR. The pac operon was PCR-
amplified based on the template plasmid, pTrc100catPAC using the primer pair (i.e. H5s-
P1s.insertion and H6as-P2as.insertion) with homology extensions targeting lacI-mhpR. H1, H2, 
H3, H4, H5 and H6 represent homology extensions, whereas P1, P2, P3 and P4 represent 
priming sites. Various primers, i.e. cynX-Fw, lacI-Rv, pac-Fw, pac-Rv, fnrS-Fw and ttcA-Rv, 
are used for colony PCR to verify the genotype of recombinant derivatives. 
 
3.2 Analytical methods 
Cell extracts were prepared by centrifuging bacterial cultures corresponding to 20 OD units at 2 °C 
and 6000×g for 15 min, followed by sonication of the resuspended pellet in 1 mL of sodium 










































supernatant containing the soluble fraction was used as the cell lysate for various enzyme assays. The 
expression of pac was qualitatively visualized by the microbiological screen with S. marscescens 
(69). The penicillin acylase activity was assayed using penicillin G as a substrate and the hydrolysis 
product of 6-aminopenicilanic acid (6-APA) was quantified by a colorimetric method (70). The 
expression of palB was qualitatively visualized by the hydrolysis of tributyrin on an agar plate (71). 
The lipase activity was assayed using olive oil as a substrate and the liberated fatty acids were 
quantified by a pH-stat (64). One unit of enzyme activity is defined as the amount of lipase required 
to liberate one μmole of fatty acid per min. Strains were regenerated three times by re-streaking 
colonies serially on LB agar plates, and the final regenerated strains were used in colony PCR and 





4.1 Single gene replacement  
Two heterologous genes previously studied in our lab, i.e. pac from E. coli ATCC11105 and palB2 
from P. antarctica, were used for demonstration purposes because they both have an easy protocol 
for phenotypical screening. In the first demonstration, we conducted the replacement of the lacZYA 
genes with pac whose expression was regulated by the trc promoter (Figure 3.2). The recombineering 
protocol (16) was used with pTrc100catPAC as a template vector. The 3.2-kb DNA fragment 
containing the Ptrc-regulated pac gene and FRT-flanked Cm
R
 marker was first amplified by 
touchdown PCR in order to avoid amplification of non-specific PCR amplicons. The PCR product 
flanked with the 36-bp homologous extensions on both termini targeting the lacZYA genes was 
transformed into E. coli HB101 for mediating genomic recombination, resulting in a Cm
R
 
recombinant derivative termed as HB101PACCmR. The Cm
R
 allele in HB101PACCmR was deleted 
by the FLP-FRT recombination to form a Cm
S
 recombinant derivative, HB101PAC. The pac and lac 
phenotypes of recombinant derivatives were respectively confirmed by the microbiological screen 
using S. marscescens and the blue-white screening using X-gal agar plates (Figure 4.1A and B). 
Colony PCR using locus-specific primer pairs confirmed the genotypes of recombinant derivatives 
(Figure 4.2D). 
Similarly, we conducted the replacement of the dbpA gene, which encodes a non-essential 
RNA helicase (72), with palB2 whose expression was regulated by the araB promoter (Figure 3.3). 
This gene replacement was carried out in both HB101 and DH5α backgrounds. However, only DH5α 
derivative is reported here since it is a better host for expressing palB2 (see further description 
below). The 2.7-kb DNA fragment containing the ParaB-regualted palB2 gene and FRT-flanked Kn
R
 
marker was amplified by touchdown PCR with pAr4KnPalb as the template vector. The PCR product 
flanked with 36-bp homologous extension on both termini targeting the dbpA gene was transformed 
in DH5α, generating the Kn
R
 recombinant derivative termed DH5αPalB2KnR. The Kn
R 
allele in the 
resulting strain was deleted using FLP-FRT recombination to form the Kn
S
 recombinant derivative, 
DH5αPalB2. The palB2 phenotype of this final strain was verified by visualizing lipase activity on 
tributyrin agar plates (Figure 4.1C). Colony PCR using locus-specific primers confirmed the 




Third generation strain colonies were tested with phenotypic assays and colony PCR for all 
the recombinant strains to ensure the stability of the integrants. Recombinant colonies were re-
streaked and isolated on LB agar as described in Material and Methods (section 3.1). 
4.2 Multiple gene replacements 
To demonstrate the extensive application of the proposed approach for “tailoring” E. coli strains, we 
conducted multiple gene replacements by respectively replacing the two non-essential alleles (i.e. 
lacZYA and dbpA) with two foreign genes (i.e. pac and palB2, Figure 3.2 and Figure 3.3 
respectively). The above-described procedure for replacing the dbpA gene with palB2 was conducted 
under the genetic background of HB101PAC. As a result, an antibiotic marker-less strain, 
HB101PACPalB2, was derived and the genotypes and phenotypes were verified by colony PCR 



















Figure 4.1 Phenotypical verification by various screening plates of recombinant derivatives. (A) 
Blue/white screening associated with lacZYA. (B) S. marscescens growth inhibition associated 
with pac. (C) Tributyrin hydrolysis associated with palB2. Recombinant derivatives: (i) HB101, 


























Figure 4.2 Genotypical verification by colony PCR of recombinant derivatives. (A) Colony PCR 
for pac knock-in. The pac-Fw and lacI-Rv primers were used to verify the presence of the 
downstream junction containing part of the pac gene and the Cm
R
 gene in the HB101PACCmR 
strain (lane 4), and to verify the Cm
S
 genotype of the HB101PAC strain (lane 5). Colony PCR of 
the wild-type HB101 strain with this primer combination was used as a negative control (lane 
1). Presence of the upstream junction containing the Ptrc-regulated pac gene was verified using 
cynX-Fw and pac-Rv primers in the HB101PACCmR and HB101PAC strains (lane 8, 9). A 
wild-type HB101 colony was used as template with this primer combination as a negative 
control (lane 7). The presence of the pac gene was verified using pac-specific primers, pac-Fw 
and pac-Rv, in the HB101PACCmR and HB101PAC strains (lane 13, 14). HB101 and HB101 
containing the pTrcKnPAC2902 colonies were used for colony PCR as negative and positive 
controls (lane 11, 15), respectively, with the pac-specific primers. (B) Colony PCR for palB2 
knock-in. Colony PCR with the fnrS-Fw and ttcA-Rv primers was used to verify the 
replacement of the dbpA gene with the DNA fragment containing ParaB-regulated palB2 gene 
and Kn
R 
gene in the HB101PACPalB2KnR strain (lane 3), and the removal of the Kn
R
 gene in 
the HB101PACPalB2 strain (lane4). The HB101PAC colony was used for colony PCR with the 




4.3 Gene insertions 
In addition to gene replacement, we also demonstrated that the proposed approach can be readily 
used to insert foreign genes into the E. coli genome. To do this, the above-described pac operon was 
inserted between the two adjacent genes in E. coli HB101 genome, i.e. lacI, encoding the lac 
repressor (73), and mhpR, encoding the hydroxyphenylpropionate regulator protein (74), without 
inactivating any genes on the E. coli chromosome. The insertion resulted in the derivation of another 
antibiotic marker-less strain, HB101PACins. The genotypes and phenotypes were verified using 
colony PCR and microbiological screen using S. marscescens, respectively (Figure 4.3 and Figure 
4.4).  
The stability of integrated DNA was tested by performing colony PCR with locus specific 
primers for eight generations (Figure 4.3). These results suggest that this advanced recombineering 






Figure 4.3 Genotypical verification by colony PCR of the HB101PACins derivative. Locus-
specific primers were used to amplify 700 bp of the Cm
R
 gene in the integrated insert. Lanes 1 
to 8 represent colonies from eight generations. Colonies were regenerated by streaking the 
colony on LB agar. 
 
 
Figure 4.4 Phenotypical verification by the HB101PACins recombinant derivatives using a S. 
marscescens microbiology screen test. The PAC activity is visualized using S. marscescens 




4.4 Regulation of foreign gene expression 
The expression of the pac and palB2 genes in the derived antibiotic marker-less strain 
HB101PACPalB2 was investigated. Since the trc and araB promoters were used to respectively 
regulate the expression of pac and palB2, cultivations supplemented with IPTG and arabinose at 
various concentrations were conducted. Control cultures without IPTG supplementation and cultures 
supplemented with IPTG after a four hour growth period were cultured in shake flasks in parallel, 
and PAC activites of these cultures were analyzed four hours after inoculation. The control culture 
had a low basal specific PAC activity of approximately 12 U/L/OD600, whereas the specific PAC 
activity gradually increased for cultures with IPTG supplementation in the range of 0.05~0.5 mM 
(Figure 4.5). The specific PAC activity reached a saturated level at 61 U/L/OD600 when IPTG 
concentration was at or above 0.5 mM. In other words, the expression of the heterologous pac gene, 
which was integrated onto the E. coli genome, could be effectively modulated through IPTG 
supplementation with an approximately five-fold inducibility in the expression level.  
These HB101PACPalB2 culture lysates were also used for conducting the lipase assay. 
Although the lipase activity was qualitatively detected based on the clear halos developed on 
tributyrin-agar plates (Figure 4.1C), the activity appeared to be too low to measure using the pH-stat 
method, even under various induction conditions with arabinose supplementation. It was our previous 
observation that HB101 was a relatively poor host for expressing the heterologous palB2 gene, 
particularly in comparison with DH5α (75). To further verify this observation, the expression of 
palB2 based on the plasmid pAr4KnPalb in the two hosts of DH5α and HB101 was investigated. The 
specific lipase activity of the arabinose-induced DH5α (pAr4KnPalb) was more than seven-fold that 
of HB101 (pAr4KnPalb), i.e. 454 U/L/OD600 vs. 61 U/L/OD600. Therefore, we constructed another 
recombinant derivative similar to HB101PalB2 under the genetic background of DH5α, namely 
DH5αPalB2KnR harboring the heterologous palB2 operon in its genome. Using DH5αPalB2KnR, 
the expression of the palB2 gene was investigated and the results are summarized in Figure 4.6. The 
control culture without arabinose supplementation had a low basal specific lipase activity of 
approximately 22 U/L/OD600, whereas the expression could be induced to reach a specific lipase 
activity of approximately 76 U/L/OD600 when arabinose was supplemented at a concentration higher 
than 10 g/L. The results suggest the effective modulation of the expression of palB2, which was 





















Figure 4.5 Expression of pac in HB101PACPalB2 under various induction conditions. PAC 
activity were assayed as described in the Materials and Methods (section 3.2, (70). Cultures 
grown in parallel were induced with various concentrations IPTG, in triplicate, four hours 
after inoclulation with 10% (v/v) of overnight culture grown at 37ºC  for 16 hours. All cultures 
were grown at 30ºC for a total of 8 hours, and showed similar growth characteristics. 20 OD600 
units of each culture were collected by centrifugation, and cell-free extracts were prepared as 

















































Figure 4.6 Expression from palB2 gene in DH5αPalB2KnR under various induction conditions. 
Lipase activities were assayed by the pH-stat method, as described in the Materials and 
Methods (section 3.2, (70). 10% (v/v) of overnight culture grown at 37ºC  for 16 hours was used 
to incolulate sample cultures grown in parallel. The sample cultures were induced with various 
concentrations L-arabinose, in triplicate, four hours after inoclulation. All cultures were grown 
at 30ºC for a total of 8 hours, and showed similar growth characteristics. 20 OD600 units of each 
culture were collected by centrifugation, and cell-free extracts were prepared as described in 









































Cell densities of plasmid-bearing HB101 strains and the recombineered HB101 strains were collected 
during fermentation and plotted to compare the growth characteristics of these strains (Figure 4.7). 
These results show that the recombineered HB101 strains can reach higher cell densities than 
plasmid-bearing HB101 strains. 
 
 
Figure 4.7 Growth curves of various HB101 and HB101-derivative strains used in this study. 
Wild-type HB101 (blue diamonds), the recombineered strains HB101PAC (brown squares) , 
HB101PalB (green triangles) ,  HB101PACPalB (purple crosses) and the plasmid-bearing 
strains HB101 (pTrc100catPAC) (blue crossed diamonds) and HB101(pAr4KnPalB) (orange 
circles) were grown in 25 ml LB broth in shake flasks incubated at 37ºC. All cell density values 































The recombineering method, based on λ Red and FLP-FRT recombinations, is a powerful tool 
commonly used to delete genes from the E. coli genome (16, 18). In this study, we have proposed a 
systematic approach based on the recombineering method for more extensive genomic engineering of 
E. coli. We have successfully inserted and replaced multiple genes within the bacterial genome.  
 
This knock-in approach has four major steps. First, a template vector should be derived 
(Figure 3.1). Virtually, any expression vector can be used as a starting construct. The gene(s) of 
interest fused with various regulatory elements and the antibiotic marker gene flanked with two FRT 
sites are respectively cloned to derive the template plasmid. Second, the DNA region containing the 
gene(s) of interest to be knocked-in, various regulatory elements, and the antibiotic marker is 
amplified by PCR using a primer pair with overhang termini homologous to the targeted site of the 
genome. Third, the amplified PCR product is introduced into E. coli host cells for mediating λ Red 
recombination and recombinant cells are selected against an appropriate antibiotic. Finally, the 
antibiotic resistance gene in the genome of recombinant cell is deleted with FLP-FRT recombination 
to form an antibiotic marker-less derivative. The approach retains several technical advantages 
associated with the original recombineering protocols, such as the availability of various antibiotic 
markers and the derivation of antibiotic marker-free recombinants. Since the heterologous genes are 
integrated into the genome instead of being carried by a multicopy plasmid, technical issues, such as 
genetic stability and metabolic burden, no longer exist. Since the antibiotic marker is removed after 
the heterologous gene is introduced, the approach can be repeated to knock-in multiple genes in 
different genomic loci. Alternatively, multiple genes can be cloned into the same template vector for 
simultaneous knock-in at the same genomic locus. 
Multiple insertions of genes using this method introduce multiple FRT sequences into the E. 
coli genome. This may raise concerns regarding undesired homologous recombinatons between these 
FRT sequences that may delete part of the genome, including essential genes. However, we have not 
found any literature reporting undesired DNA excision due to homologous recombination between 
the FRT sites in E. coli (13, 76). Moreover, multiple regenerations of the HB101PACPalB2, which 
has two FRT sites, in liquid culture and solid agar media always yielded colonies similar to the parent 





 gene) was regenerated eight times. Colony PCR of the regenerated strains shows 
that the inserted genes are stable in each generation.  This further proves that undesired excision of 
DNA by homologous recombination between the FRT sites is unlikely. 
Given the flexible and extensive natures associated with the proposed approach, several 
technical aspects should be considered. First, the primers used to amplify the knock-in DNA 
fragment containing at least a heterologous gene and an antibiotic marker are large in size (up to 56 
base pairs in this study). Large primers tend to bind to the template DNA non-specifically during 
PCR, causing amplification of erroneous DNA fragments (68). Although the correct DNA insert can 
be isolated using gel extraction, the low DNA recovery and poor DNA quality significantly affect the 
subsequent cloning. In this study, touchdown PCR (68) was used to resolve this issue. Second, the 
strain used in this approach should be carefully selected since the genetic background could affect 
certain applications (77). For example, BL21 appears to be an unsuitable host for this approach due to 
a poor transformation efficiency of either electroporation or P1-phage transduction . Also, HB101 
was a poor host for expressing the palB2 gene in this study. Although the reason is unknown, this 
observation is consistent with previous literature studying the expression from the palB2 gene in 
HB101 (75). Third, while the heterologous gene can be knocked-in either via gene insertion or gene 
replacement, it appears that the efficiency of gene insertion is significantly lower than that of gene 
replacement possible due to the lack of a sizable DNA fragment between the two homologous arms. 
In this study, we observed that the recombination efficiency for inserting pac between lacI and mhpR 
was at least 90% lower than that for replacing lacZYA with pac. Finally, targeted sites for genomic 
engineering, either knock-in or knockout, should be carefully determined. These chosen target sites 
should not be part of an essential gene.  Also, presumably, DNA regions that are not well exposed for 
recombination should be avoided though it might be hard to systematically identify these regions. 
In addition to the construction of various knock-in E. coli strains, we also showed the 
capacity of the proposed approach for regulating the expression of heterologous genes that are 
integrated into the genome. The demonstration represents a potential advantage for several 
biotechnological applications, such as metabolic engineering which often requires expressional fine-
tuning of a selection of genes for optimal production of target metabolites. 
Recombineered strains carrying a chromosomal copy of the protein-encoding genes can reach 
slightly better cell densities than plasmid-bearing strains. In this study, the recombineered HB101 
strains carrying a chromosomal copy of the gene(s) of interest showed up to 1 OD600 unit better cell 
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density than plasmid-bearing HB101 strains. This difference is growth rate is presumably due to the 






Genomic engineering has become a popular tool for manipulation of microbial strains. The 
availability of recombineering protocols and genomic sequences significantly facilitates the 
manipulation. However, most of the protocols for genomic engineering focus on gene knockout. To 
complement the technical deficiency, we have proposed a systematic approach based on the λ Red 
and FLP-FRT recombinations to introduce foreign genes into the E. coli genome.  
Using the two heterologous genes of pac and palB2, various scenarios for gene knock-in 
(including both gene insertion and gene replacement) were demonstrated in this study. The final 
recombinant strains are marker-less strains, which allows researchers to repeat this strategy to insert 
any number of genes into the genome. Whereas plasmid-based expression of genes requires antibiotic 
pressure to maintain gene copy during cultivation, antibiotics are not necessary with recombinant 
derivatives engineered using the proposed strategy. Furthermore, expression of these genes can be 
regulated using inducible promoter systems, as also demonstrated in this study. 
By proposing a systematic approach for knocking-in heterologous genes to the E. coli 
genome, this study has paved a way towards developing a more comprehensive genomic engineering 
strategy for “strain tailoring”. Foreign pathways can be introduced into model bacterial genomes for 
the safe and controlled overproduction of economically valuable metabolites. Currently, we are 
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Molecular Cloning Protocols 
A.1 Isolation of Genomic DNA of E. coli  
 (DNeasy® Blood and Tissue Kit, Qiagen) 
1. Harvest E. coli BW25141 strain from a 10 mL overnight culture (grown at 37ºC at 225 rpm) 
by centrifuging for 10 minutes at 10,000 rpm at room temperature. Discard supernatant. 
2. Resuspend pellet in 180 µL of Buffer ATL. 
3. Add 4 μl RNase A provided, vortex and incubate at room temperature for 2 minutes. 
4. Add 20 μl proteinase K. Mix by vortexing, and incubate at 56°C until the cells are 
completely lysed. 
5. Add 200 μl Buffer AL to the sample, and vortex for 1 minute. Add 200 μl  of 96% ethanol, 
and vortex for another minute. 
6. Pipette the mixture from step 3 into the DNeasy Mini spin column placed in a 2 mL 
collection tube. Centrifuge at 8000 rpm for 1 minute. Discard flow-through and collection 
tube. 
7. Place the DNeasy Mini spin column in a new 2 mL collection tube, add 
8. 500 μl Buffer AW1, and centrifuge for 1 minute at 8000 rpm. Discard flow-through and 
collection tube. 
9. Place the DNeasy Mini spin column in a new 2 mL collection tube, add 500 μl Buffer AW2, 
and centrifuge for 3 minutes at 14,000 rpm to dry the DNeasy membrane. Discard flow-
through and collection tube. 
10. Place the DNeasy Mini spin column in a clean 1.5 mL microcentrifuge tube, and pipette 100 
μl Buffer AE directly onto the DNeasy membrane. 
11. Incubate at room temperature for 1 minute, and then centrifuge for 1 minute at 8000 rpm to 
elute. 
12. Repeat elution once as described in step 10. 
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13. Quantify DNA concentration using a Nanodrop® spectrophotometer, and store at -20ºC. 
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A.2 Plasmid DNA extraction from E. coli 
(Qiaprep Spin Miniprep Kit, Qiagen) 
1. Add the provided RNase A solution to Buffer 1 and mix. 
2. Harvest the plasmid-bearing E. coli strain from a 10 mL overnight culture (grown at 37ºC at 
225 rpm with appropriate antibiotic) by centrifuging for 10 minutes at 10,000 rpm at room 
temperature. Discard supernatant. 
3. Resuspend pelleted bacterial cells in 250 μl Buffer P1 and transfer to a microcentrifuge tube. 
4. Add 250 μl Buffer P2 and mix thoroughly by inverting the tube 4–6 times. 
5. Add 350 μl Buffer N3 and mix immediately and thoroughly by inverting the tube 5 times. 
6. Centrifuge for 10 minutes at 13,000 rpm in a microcentrifuge. A compact white pellet will 
form. 
7. Apply the supernatants to the QIAprep spin column by pipetting. 
8. Centrifuge for 1 minute. Discard the flow-through. 
9. Wash the QIAprep spin column by adding 0.5 mL Buffer PB and centrifuging for 1 minute. 
Discard the flow-through. 
10. Wash QIAprep spin column by adding 0.75 mL Buffer PE and centrifuging for 1 minute. 
11. Discard the flow-through, and centrifuge for an additional 1 min to remove residual wash 
buffer. 
12. Place the QIAprep column in a clean 1.5 mL microcentrifuge tube. To elute DNA, add 50 μl 
Buffer EB (10 mM Tris·Cl, pH 8.5) to the center of each QIAprep spin column, let stand for 
1 minute, and centrifuge for 1 minute. 




A.3 Restriction Digest of Plasmid or Insert DNA 
1. Set up restriction digest as in a micro centrifuge tube, on ice, as follows: 
Component Stock  
Concentration 
Required Concentration Volume 
Reaction Buffer* 10X 1X 3 µL 
DNA 50-200 µg/ml 25-50 ng 0.25-2 µL 
Restriction Enzyme(s) 10,000-20,000 U/mL 10 U 0.5-1 µL 
Deionised Water   Up to 30µL 
Total   30 µL 
* Supplied reaction buffers for restriction enzymes were used. 
2. Mix the reaction by tapping the microcentrifuge tubes gently. 
3. Incubate the mixture at supplier’s recommended temperature (37ºC for most restriction 
enzymes used in this study) for at least 1 hour. 
4. Inactivate enzyme by heating at supplier’s recommended temperature (65ºC for most 
restriction enzymes used in this study) for 20 minutes. 
5. Purify digested DNA fragments using a PCR purification kit. Alternatively, specific digested 
fragments can be isolated by gel electrophoresing the digestion mixture through a 0.75% low 
melt agarose gel, excising a piece of the gel containing the fragment of interest, and 
extracting the fragment through a gel extraction kit. 
A.4 DNA Ligation 
1. Digest the plasmid or insert DNA with appropriate restriction enzymes (see section A.3). 
2. Isolate and extract the desired plasmid DNA fragment by gel electrophoresis and gel 
extraction kit, and quantify using a Nanodrop® spectrophotometer. 
3. PCR purify the insert digestion, and quantify using a Nanodrop® spectrophotometer. 
4. Set up the ligation reaction as follows, on ice: 
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Component Amount Volume 
Insert DNA 0.1-1 µg  
DNA 0.05-1 µg  
Ligation buffer  1 µL 
T4 DNA Ligase 0.1 Weiss Units 0.2 µL 
Deionised Water  Up to 10 µL 
Total  10 µL 
 
5. Mix reaction mixture by tapping the tube gently. 
6. Incubate the reaction mixture 1-4 hours at room temperature. 
7. Purify DNA using PCR purification kit, elute with 10 µL deionized, sterile water. 
8. Transform entire elution in E. coli DH5α strain via electroporation. 
A.5 Gel Extraction of DNA fragments 
(QiaexII  Gel Extraction Kit, Qiagen) 
1. Excise the DNA band from the agarose gel with a clean, sharp scalpel. 
2. Weigh the gel slice in a colorless tube. Add 3 volumes of Buffer QX1 to 1 volume of gel. 
3. Resuspend QIAEX II by vortexing for 30 seconds. Add 30 µL of QIAEX II to the sample 
according and mix. 
4. Incubate at 50°C for 10 minutes to solubilize the agarose and bind the DNA. Mix by 
vortexing every 2 minutes to keep QIAEX II in suspension. Check that the color of the 
mixture is yellow. 
5. Centrifuge the sample for 30 seconds and carefully remove supernatant with a pipette. 
6. Wash the pellet with 500 μl of Buffer QX1. 
7. Wash the pellet twice with 500 μl of Buffer PE. 
8. Air-dry the pellet for 15 minutes or until the pellet becomes white. 
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9. To elute DNA, add 20 μl of sterile deionised water and resuspend the pellet by vortexing. 
Incubate at 50ºC for 10 minutes. 
10. Centrifuge for 1 minute, and carefully pipette the supernatant into a clean microcentrifuge 
tube. 
11. Quantify DNA using a Nanodrop® spectrophotometer, and store at -20ºC. 
. 
A.6 Purification of PCR-amplified DNA 
(QIAquick PCR Purification Kit, Qiagen) 
1. Add 96% ethanol to Buffer PE. 
2. Add 5 volumes of Buffer PB to 1 volume of the PCR sample and mix. 
3. Place a QIAquick spin column in a provided 2 ml collection tube. 
4. To bind DNA, apply the sample to the QIAquick column and centrifuge for 1 minute. 
5. Discard flow-through. Place the QIAquick column back into the same tube. 
6. To wash, add 0.75 ml Buffer PE to the QIAquick column and centrifuge for 1 minute. 
7. Discard flow-through and place the QIAquick column back in the same tube. Centrifuge the 
column for an additional 1 minute at maximum speed.  
8. Place QIAquick column in a clean 1.5 ml microcentrifuge tube. 
9. To elute DNA, add 30 μl sterile deionised water to the center of the QIAquick membrane and 
centrifuge the column for 1 minute. 
10. Let the column stand for 1 minute, and then centrifuge. 
11. Quantify DNA using a Nanodrop® spectrophotometer, and store at -20ºC. 
A.7 DNA Transformation using Electroporation 
(Modified from Electroporation Manual, BioRad) 
Preparation of Electrocompetent Cells 
 
1. Inoculate 100 ml of L-broth with 1/100 volume of a fresh overnight E. coli culture. 
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2. Grow the cells at 37 °C shaking at 200 rpm to an OD600 of approximately 0.5–0.7. 
3. Chill cells on ice for ~20 min. For all subsequent steps, keep the cells as close to 0 °C as possible 
(in an ice/water bath) and chill all containers in ice before adding cells. To harvest, transfer the cells 
to two cold 60-ml centrifuge bottles and spin at 6000 x g for 15 minutes at 4 °C. 
4. Carefully pour off and discard the supernatant. It is better to sacrifice the yield by pouring off a 
few cells than to leave any supernatant behind. 
5. Gently resuspend the pellet in 50 ml of ice-cold 10% glycerol each. Centrifuge at 6000 x g for 15 
minutes at 4 °C; carefully pour off and discard the supernatant. 
6. Resuspend the pellet in 50 ml of ice-cold 10% glycerol, transfer to one 60-ml bottle. Centrifuge at 
6000 x g for 15 minutes at 4 °C; carefully pour off and discard the supernatant. 
7. Resuspend the pellet in ~4 ml of ice-cold 10% glycerol. Transfer to two 2-ml sterile microfuge 
tubes. Centrifuge at 6000 x g for 15 minutes at 4 °C; carefully pour off and discard the supernatant. 
8. Resuspend the cell pellet in a final volume of 400μl of ice-cold 10% glycerol. The cell 
concentration should be about 1–3 x 1010 cells/ml. This suspension may be frozen in aliquots (40μl 
each in a sterilized 1.5ml microfuge tube) on dry ice and stored at -80 °C. The cells are stable for at 
least 6 months under thes  
conditions. 
Electroporation 
1. Thaw the cells on ice. For each sample to be electroporated, place a 1.5 ml microfuge tube and 
either a 0.1 or 0.2 cm electroporation cuvette on ice. 
2. In a cold, 1.5 ml polypropylene microfuge tube, mix 40 μl of the cell suspension with 1 to 2 μl of 
DNA (DNA should be in deioned water). Mix well and incubate on ice for approximately 1 minute. 
(Note: it is best to mix the plasmids and cells in a microfuge tube since the narrow gap of the cuvettes 
prevents uniform mixing.) 
3. Set the MicroPulser to “Ec1” when using the 0.1 cm cuvettes. Set it to "Ec2" or "Ec3" when using 
the 0.2 cm cuvettes. See Section 4 for operating instructions. 
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4. Transfer the mixture of cells and DNA to a cold electroporation cuvette and tap the suspension to 
the bottom. Place the cuvette in the chamber slide. Push the slide into the chamber until the cuvette is 
seated between the contacts in the base of the chamber. Pulse once. 
5. Remove the cuvette from the chamber and immediately add 1 ml of SOC medium to the cuvette. 
Quickly but gently resuspend the cells with a Pasteur pipette. (The period between applying the pulse 
and transferring the cells to outgrowth medium is crucial for recovering E. coli transformants (Dower 
et al., 1988). Delaying this transfer by even 1 minute causes a 3-fold drop in transformation. This 
decline continues to a 20-fold drop by 10 minutes. 
6. Transfer the cell suspension to a 17 x 100 mm polypropylene tube and incubate at 37 °C for 1 
hour, shaking at 225 rpm. 
7. Check and record the pulse parameters. The time constant should be close to 5 milliseconds. The 
field strength can be calculated as actual volts (kV) / cuvette gap (cm). 
8. Plate on selective medium. 
Solutions and Reagents for Electroporation 
1. L-Broth: 10 g Bacto tryptone, 5 g Bacto yeast extract, 5 g NaCl; dissolve in 1.0 L water. 
Autoclave. 
2. 10% (v/v) Glycerol: 12.6 g glycerol (density = 1.26 g/cc) in 90 ml of water. Autoclave or filter 
sterilize.  
3. SOC: seperately autoclave, 
(1) 2% Bacto tryptone, 0.5% Bacto yeast extract, 10 mM NaCl, 2.5 mM KCl, 
(2) 10 mM, MgCl2, 
(3) 10 mM MgSO4, 





Restriction Mapping and Analysis of the Plasmids 
The following plasmid maps were constructed in Vector NTI software by Invitrogen. Restriction 
enzymes EcoRI and HindIII were used for restriction analysis of plasmids. DNA gels were obtained 
by gel electrophoresis method.  
 
Figure B.0.1 Restriction Analysis of pAR4Kn vector. Restriction digest by EcoRI restriction 
enzyme gave the expected band at 4.8 kb (Lane 1). The remaining bands in lane 1 correspond 
to the uncut vector, as they are also present in the negative control lane (lane 3, uncut plasmid). 



















Figure B.0.2 Restriction Analysis of template vector pAR4KnPalB2. Restriction digest by 
EcoRI restriction enzyme gave the expected bands at approximately 3.1 kb and 2.9 kb (Lane 1). 
The remaining bands in lane 1 correspond to the uncut vector, as they are also present in the 
negative control lane (lane 3, uncut plasmid). Restriction digest by HindIII also shows the 




















Figure B.0.3 Restriction Analysis of pTrc100cat. Separate restriction digests by EcoRI (lane 1) 
and HindIII (lane 2) restriction enzymes linearized the vector, yielding the expected bands at 
5.2 kb. The remaining bands in lane 1 correspond to the uncut vector, as they are also present 





















Figure B.0.4 Restriction Analysis of template vector pTrc100catPAC. Restriction digest by 
EcoRI restriction enzyme linearized the vector, yielding the expected band at ~ 8 kb (Lane 1). 
The remaining bands in lane 1 correspond to the uncut vector, as they are also present in the 
negative control lane (lane 3, uncut plasmid). Restriction digest by HindIII also shows the 
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